What is the Current Share Price of Morepen Laboratories Ltd?
- Answer Field
-
Morepen Laboratories Ltd share price is for NSE ₹ 61.77 & for BSE ₹ 61.78 as on Jun 30 2025 03:30 PM.
BAJAJ BROKING
Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply
As of the latest trading session, Morepen Laboratories share price is currently at ₹ 61.77, which is down by ₹ -0.98 from its previous closing. Today, the stock has fluctuated between ₹ 61.10 and ₹ 63.75. Over the past year, Morepen Laboratories has achieved a return of 16.95 %. In the last month alone, the return has been -5.86 %. Read More...
Particulars | MAR 2025 (Values in Cr) |
---|---|
Revenue | 381.94 |
Operating Expense | 367.77 |
Net Profit | 11.91 |
Net Profit Margin (%) | 3.11 |
Earnings Per Share (EPS) | 0.20 |
EBITDA | 33.29 |
Effective Tax Rate (%) | 31.15 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 37.35 | 28.51 | 2.04 | 286.23 | 34.11 / 77.70 |
BLISS GVS PHARMA LTD | 157.85 | 19.73 | 1.58 | 1663.27 | 101.00 / 184.95 |
CIPLA LTD | 1502.75 | 23.59 | 3.89 | 121378.29 | 1310.05 / 1702.00 |
FERMENTA BIOTECH LIMITED | 323.55 | 12.39 | 2.62 | 952.24 | 163.00 / 449.00 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 37.35 | 37.35 | 5.90 | 286.23 | 34.11 / 77.70 |
AMRUTAJAN HEALTH LTD | 728.50 | 41.44 | 6.44 | 2106.14 | 548.05 / 861.40 |
ASTRAZENECA PHARMA IND LT | 8896.30 | 127.05 | 28.87 | 22240.75 | 6171.25 / 10653.05 |
BLISS GVS PHARMA LTD | 157.85 | 24.10 | 1.57 | 1663.27 | 101.00 / 184.95 |
In the second quarter of fiscal year 2024-25, Morepen Laboratories Limited reported a consolidated net profit of ₹21.26 crore, marking a 45% increase from ₹14.63 crore in the previous quarter. Revenue from operations rose by 5.2% quarter-on-quarter to ₹421.77 crore. The company's EBITDA margin improved to 12.25%, reflecting enhanced operational efficiency. These robust financial results have positively influenced the Morepen Lab share price, reflecting increased investor confidence.
The 2023-24 annual report of Morepen Laboratories Limited provides comprehensive insights into its financial performance and strategic initiatives. The company achieved a total income of ₹1,744.6 crore, registering a growth of 7.7% from the previous year. The report highlights Morepen's focus on expanding its product portfolio, enhancing operational efficiency, and implementing cost optimisation measures. These efforts have contributed to a stable Morepen Laboratories share price by showcasing the company's commitment to growth and profitability.
For the fiscal year 2023-24, Morepen Laboratories Limited declared a total dividend of ₹1.50 per share, reflecting its commitment to returning value to shareholders. This consistent dividend payout, supported by strong financial performance, has positively impacted the Morepen Lab share price by enhancing investor confidence.
Morepen Laboratories Limited is an India-based pharmaceutical company. Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin. The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast. It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L.
The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India. The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally. The company has developed a hi-tech Pharma complex at Morepen Village, Baddi (HP) on 60 acres of land that has various multipurpose pharma facilities for API & finished dosages and a Research Centre.
Morepen Laboratories Limited was established in 1984. The company has filed 14 patents including 6 international PCT applications. The company has filed an international patent on a new amorphous form of the cholesterol-reducing drug Lipitor (Atorvastatin) that is the largest selling drug in the world. During the year 1991-1992, the company set up the new facilities for bulk manufacture of Cephalexin, 7 ADCA and CIMC Chloride at its existing location. During the year 1992-1993, the company started implementing its expansion plans for manufacture Cephalexin, 7ADCA, CIMC Chloride, Research and Development Block and Formulation unit. The company introduced two latest molecules, Ketrolac Tromethamine and Omeprazole. Also, the company also launched Loratadine and Cisapride.
During the year 1993-1994, the company increased the installed capacity of Bulk Drugs from 162 MT to 245 MT. The company started the commercial production of Ketorolac Tromethamine, which is a potent analgesic. During the year 1994-1995, the company increased the installed capacity of Drugs & Drug Intermediates from 305 MT to 469 MT.
During the year 1995-1996, the company successfully launched high value and high technology products namely, Cisapride & Loratadine. Also, the company launched herbal product namely Paclitaxel, an anti cancer drug. During the year 1996-1997, the company commissioned its own formulation unit, which gave a competitive edge to the company in terms of quality and cost efficiency.
During the year 2000-2001, the company increased the installed capacity of Drugs & Drug Intermediates from 916 MT to 1170 MT. The company signed a joint venture with DiaMed AG of Switzerland, a proven international leader in blood group serology diagnostic products. Also, the company developed and launched wide range of contemporary, lifestyle oriented FMHG (Fast Moving Health Goods) Self Medication products.
During the year 2001-2002, the company increased the installed capacity of Drugs & Drug Intermediates from 1170 MT to 1251 MT. Also, the company further increased installed capacity of Tablets / Capsules from 25080 Nos to 35000 Nos. During the year 2004-2005, the company developed the new polymorphic from V1 and field patent in 33 countries and in the same year, the company started finalizing marketing partner for filing ANDA's for the molecule.
During the year 2005-2006, the company made 52 DMF filing across ten European countries for six products. Also, the company broadened its offering by introduced new product like Ducal, Rythmix, Montelast, Alcoflam, Levopen, Moezole, and Cefpen-S.
During the year 2006-2007, the company improved its presence in the key market of South East Asia, Africa & Australia. During the year, the company acquired more than fifty new prospective customers in Korea, Japan, and Taiwan. During the year, the company started of OTC formulation under the umberalla brand 'Dr. Morepen'.
During the year 2007-2008, the company made the tie ups with several new business segments. Marketing alliance with World leaders like lmmucor, USA (for immuunohematology system & consumables), Teco Medical Instruments, Germany (for coagulation system & consumables), InTec INC. (for ELISA Kits), Access Bio, USA (for Rapid Malaria Kits), helped the diagnostics division to make deeper inroads into both the consumer market and the blood bank and laboratory segment.
In 2010, it launched Cardia Division for Diabetic and Cardiac products. In 2015, it started personal Grooming Division with brand GUBB USA. In 2019, it launched APIs for many anti-diabetic molecules. The Company launched 'IntebactImun' in boosting immunity of adults and kids in 2023. It started manufacturing two more products viz., Blood Pressure Monitors and Pregnancy Testing Kits in 2023.
During the year 2024, new capacities were built for manufacture of tablets wherein tablet manufacture capacity were increased to 162 units from 92.40 units in 2022-23. The capacities for capsule, oral liquid, sachet and dry syrup has also be enhanced in FY24.
Morepen Laboratories Ltd share price is for NSE ₹ 61.77 & for BSE ₹ 61.78 as on Jun 30 2025 03:30 PM.
The market cap of Morepen Laboratories Ltd for NSE ₹ 3,157.48 & for BSE ₹ 3,158.00 as on Jun 30 2025 03:30 PM.
The 52 Week High and Low of Morepen Laboratories Ltd for NSE is ₹ 100.90 and ₹ 42.00 and for BSE is ₹ 100.80 and ₹ 41.66.
The 1 year returns on the stock has been 16.95%.
As on Jun 30 2025 03:30 PM the price-to-earnings (PE) ratio for Morepen Laboratories Ltd share is 33.94.
As on Jun 30 2025 03:30 PM, the price-to-book (PB) ratio for Morepen Laboratories Ltd share is 21.56.
You can trade in Morepen Laboratories Ltd shares with Bajaj Broking by opening a demat account.
To buy Morepen Laboratories Ltd shares on the Bajaj Broking app, follow these steps:
• Login to the Bajaj Broking App
• Click on the Search Icon
• Search “Morepen Laboratories Ltd”
• Click on the BUY icon
• Place a buy order specifying the desired quantity of shares.
• Click BUY again to complete the purchase
No results found